Alliancebernstein L.P. reduced its position in shares of Synergy Pharmaceuticals (NASDAQ:SGYP) by 64.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 239,030 shares of the biopharmaceutical company’s stock after selling 435,300 shares during the quarter. Alliancebernstein L.P. owned about 0.10% of Synergy Pharmaceuticals worth $533,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SGYP. JPMorgan Chase & Co. increased its holdings in Synergy Pharmaceuticals by 71.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,405,377 shares of the biopharmaceutical company’s stock worth $8,820,000 after purchasing an additional 1,417,177 shares during the period. Wells Fargo & Company MN increased its holdings in Synergy Pharmaceuticals by 18.2% during the 3rd quarter. Wells Fargo & Company MN now owns 219,676 shares of the biopharmaceutical company’s stock worth $638,000 after purchasing an additional 33,802 shares during the period. Cornerstone Capital Management Holdings LLC. increased its holdings in Synergy Pharmaceuticals by 46.0% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 194,359 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 61,200 shares during the period. Hikari Power Ltd increased its holdings in Synergy Pharmaceuticals by 26.7% during the 4th quarter. Hikari Power Ltd now owns 1,900,000 shares of the biopharmaceutical company’s stock worth $4,237,000 after purchasing an additional 400,000 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its holdings in Synergy Pharmaceuticals by 11.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 1,051,408 shares of the biopharmaceutical company’s stock worth $2,345,000 after purchasing an additional 106,222 shares during the period. Institutional investors own 53.08% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:SGYP opened at $1.77 on Tuesday. Synergy Pharmaceuticals has a 12-month low of $1.68 and a 12-month high of $4.84. The firm has a market capitalization of $446.45, a PE ratio of -1.74 and a beta of 1.17. The company has a current ratio of 4.33, a quick ratio of 3.88 and a debt-to-equity ratio of -21.05.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.03. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 1,333.76%. The business had revenue of $9.40 million for the quarter, compared to the consensus estimate of $7.12 million. Synergy Pharmaceuticals’s quarterly revenue was up 840.0% compared to the same quarter last year. equities research analysts forecast that Synergy Pharmaceuticals will post -0.52 EPS for the current year.

Several research analysts have commented on the company. Cantor Fitzgerald restated a “buy” rating on shares of Synergy Pharmaceuticals in a report on Thursday, February 1st. HC Wainwright set a $7.00 price target on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 8th. Zacks Investment Research downgraded Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 17th. BidaskClub downgraded Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 23rd. Finally, CIBC reiterated a “market perform” rating on shares of Synergy Pharmaceuticals in a report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $8.08.

ILLEGAL ACTIVITY WARNING: “Alliancebernstein L.P. Trims Holdings in Synergy Pharmaceuticals (SGYP)” was originally reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/04/17/alliancebernstein-l-p-trims-holdings-in-synergy-pharmaceuticals-sgyp.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Want to see what other hedge funds are holding SGYP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synergy Pharmaceuticals (NASDAQ:SGYP).

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.